The impact of molecular and clinical factors on patient outcome in oligodendroglioma from 20years’ experience at a single centre

The increased chemosensitivity of oligodendroglial tumours has been associated with loss of heterozygosity (LOH) of the p arm of chromosome 1 and the q arm of chromosome 19 (LOH 1p/19q). Other clinical and molecular factors have also been identified as being prognostic and predictive of treatment outcome. We reviewed 105 patients with oligodendroglioma treated at a single centre over 20 years. Median survival in oligodendroglioma patients with LOH 1p/19q was significantly longer (10.9 vs. 2.0 years). In the anaplastic oligodendroglioma group, univariate analysis demonstrated decreased patient age, presentation with seizures, use of adjuvant chemotherapy and LOH 1p/19q as predictors of improved survival. Multivariate analysis confirmed LOH 1p/19q as a significant predictor of improved survival (hazard ratio, 3.4; p=0.015). Median survival in patients with anaplastic oligodendroglioma with LOH 1p/19q was 15.4 years vs. 1.2 years for those without LOH 1p/19q. This study confirms the utility of LOH 1p/19q as a prognostic marker in oligodendroglioma.

[1]  J. Herman,et al.  Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. , 2009, Neuro-oncology.

[2]  D. Louis,et al.  Survey of treatment recommendations for anaplastic oligodendroglioma. , 2007, Neuro-oncology.

[3]  B. Scheithauer,et al.  Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  D. Louis,et al.  Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. , 1998, Journal of the National Cancer Institute.

[5]  M. J. van den Bent,et al.  MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. J. van den Bent,et al.  Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features , 2003, Cancer.

[7]  S. Horvath,et al.  Gene Expression Profiling of Gliomas Strongly Predicts Survival , 2004, Cancer Research.

[8]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[9]  M. Poljak,et al.  p53 Immunoreactivity in oligodendrogliomas , 2005, Journal of Neuro-Oncology.

[10]  C. Sarkar,et al.  p53 protein alterations in adult astrocytic tumors and oligodendrogliomas. , 2004, Neurology India.

[11]  P. Kleihues,et al.  p53 mutations in nonastrocytic human brain tumors. , 1991, Cancer research.

[12]  T. Mikkelsen,et al.  Temozolomide single-agent chemotherapy for newly diagnosed anaplastic oligodendroglioma , 2009, Journal of Neuro-Oncology.

[13]  A. Lassman,et al.  Molecular profiling of oligodendrogliomas: Impact on prognosis, treatment, and future directions , 2009, Current oncology reports.

[14]  R A Betensky,et al.  Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  Walter Curran,et al.  Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  R. McLendon,et al.  Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. , 1999, The American journal of pathology.

[17]  C. V. van Eden,et al.  Expression of p53 in oligodendrogliomas , 1993, The Journal of pathology.

[18]  Denis Lacombe,et al.  Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  T. Cascino,et al.  Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  J. Cairncross,et al.  Successful chemotherapy for recurrent malignant oligodendroglioma , 1988, Annals of neurology.

[21]  S. Saikali,et al.  Oligodendroglioma: clinical study and survival analysis correlated with chromosomal anomalies. , 2005, Neurosurgical focus.

[22]  K. Ueki.  Oligodendroglioma: Impact of molecular biology on its definition, diagnosis and management , 2005, Neuropathology : official journal of the Japanese Society of Neuropathology.

[23]  A. Twijnstra,et al.  Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy , 1998, Neurology.

[24]  A. Chiò,et al.  Prognostic Factors in Oligodendroglioma , 1997, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[25]  G. Reifenberger,et al.  Analysis of p53 Mutation and Epidermal Growth Factor Receptor Amplification in Recurrent Gliomas with Malignant Progression , 1996, Journal of neuropathology and experimental neurology.

[26]  Pascale Varlet,et al.  Oligodendrogliomas. Part II: A new grading system based on morphological and imaging criteria , 1997, Journal of Neuro-Oncology.

[27]  A. Levine,et al.  The p53 tumour suppressor gene , 1991, Nature.

[28]  M. J. van den Bent,et al.  Recent developments in the molecular characterization and treatment of oligodendroglial tumors. , 2003, Neuro-oncology.

[29]  C. Hagel,et al.  Prognostic relevance of TP53 mutations, p53 protein, Ki-67 index and conventional histological grading in oligodendrogliomas. , 1999, Journal of experimental & clinical cancer research : CR.